Clinical Pharmacology of Opioids for Pain
Top Cited Papers
- 1 July 2002
- journal article
- review article
- Published by Wolters Kluwer Health in The Clinical Journal of Pain
- Vol. 18 (Supplement) , S3-S13
- https://doi.org/10.1097/00002508-200207001-00002
Abstract
The pharmacological effects of the opioid analgesics are derived from their complex interactions with three opioid receptor types (μ, δ, and κ; morphine is an agonist at the μ opioid receptor). These receptors are found in the periphery, at presynaptic and postsynaptic sites in the spinal cord dorsal horn, and in the brain stem, thalamus, and cortex, in what constitutes the ascending pain transmission system, as well as structures that comprise a descending inhibitory system that modulates pain at the level of the spinal cord. The cellular effects of opioids include a decrease in presynaptic transmitter release, hyperpolarization of postsynaptic elements, and disinhibition. The endogenous opioid peptides are part of an endogenous pain modulatory system. A number of opioids are available for clinical use, including morphine, hydromorphone, levorphanol, oxymorphone, methadone, meperidine, oxycodone, and fentanyl, and their advantages and disadvantages for the management of pain are discussed. An understanding of the pharmacokinetic properties, as well as issues related to opioid rotation, tolerance, dependence, and addiction are essential aspects of the clinical pharmacology of opioids for pain.Keywords
This publication has 32 references indexed in Scilit:
- Molecular Neurobiology of AddictionThe American Journal on Addictions, 2001
- Neuroexcitatory Effects Of Morphine And Hydromorphone: Evidence Implicating The 3‐Glucuronide MetabolitesClinical and Experimental Pharmacology and Physiology, 2000
- The role of morphine glucuronides in cancer painPalliative Medicine, 1999
- Opioids: first lessons from knockout miceTrends in Pharmacological Sciences, 1999
- Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?Journal of Clinical Oncology, 1998
- Novel receptor mechanisms for heroin and morphine-6β-glucuronide analgesiaNeuroscience Letters, 1996
- ADJUVANT ANALGESIC AGENTSHematology/Oncology Clinics of North America, 1996
- Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patientsPain, 1995
- The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal functionClinical Pharmacology & Therapeutics, 1992
- Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failurePain, 1991